JP7657711B2 - 核酸塩基編集システムを送達するための組成物および方法 - Google Patents
核酸塩基編集システムを送達するための組成物および方法 Download PDFInfo
- Publication number
- JP7657711B2 JP7657711B2 JP2021512514A JP2021512514A JP7657711B2 JP 7657711 B2 JP7657711 B2 JP 7657711B2 JP 2021512514 A JP2021512514 A JP 2021512514A JP 2021512514 A JP2021512514 A JP 2021512514A JP 7657711 B2 JP7657711 B2 JP 7657711B2
- Authority
- JP
- Japan
- Prior art keywords
- cas9
- terminal fragment
- deaminase
- sequence
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04002—Adenine deaminase (3.5.4.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04004—Adenosine deaminase (3.5.4.4)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024192680A JP7899276B2 (ja) | 2018-09-07 | 2024-11-01 | 核酸塩基編集システムを送達するための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862728703P | 2018-09-07 | 2018-09-07 | |
| US62/728,703 | 2018-09-07 | ||
| US201862779404P | 2018-12-13 | 2018-12-13 | |
| US62/779,404 | 2018-12-13 | ||
| PCT/US2019/050111 WO2020051561A1 (en) | 2018-09-07 | 2019-09-07 | Compositions and methods for delivering a nucleobase editing system |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024192680A Division JP7899276B2 (ja) | 2018-09-07 | 2024-11-01 | 核酸塩基編集システムを送達するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500017A JP2022500017A (ja) | 2022-01-04 |
| JP2022500017A5 JP2022500017A5 (cg-RX-API-DMAC7.html) | 2022-09-14 |
| JP7657711B2 true JP7657711B2 (ja) | 2025-04-07 |
Family
ID=69722796
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021512514A Active JP7657711B2 (ja) | 2018-09-07 | 2019-09-07 | 核酸塩基編集システムを送達するための組成物および方法 |
| JP2024192680A Active JP7899276B2 (ja) | 2018-09-07 | 2024-11-01 | 核酸塩基編集システムを送達するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024192680A Active JP7899276B2 (ja) | 2018-09-07 | 2024-11-01 | 核酸塩基編集システムを送達するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12529041B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3847254A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7657711B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210055733A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112969790B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019336245B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3112011A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020051561A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025028857A (ja) * | 2018-09-07 | 2025-03-05 | ビーム セラピューティクス インク. | 核酸塩基編集システムを送達するための組成物および方法 |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019051097A1 (en) | 2017-09-08 | 2019-03-14 | The Regents Of The University Of California | RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USING SAME |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| JP7646552B2 (ja) | 2019-01-31 | 2025-03-17 | ビーム セラピューティクス インク. | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| WO2020168135A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| US20220259617A1 (en) | 2019-06-13 | 2022-08-18 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| CA3147875A1 (en) | 2019-07-19 | 2021-01-28 | Flagship Pioneering Innovations Vi, Llc | Recombinase compositions and methods of use |
| US12594301B2 (en) | 2019-09-27 | 2026-04-07 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| BR112022017715A2 (pt) | 2020-03-04 | 2022-11-16 | Flagship Pioneering Innovations Vi Llc | Métodos e composições para modular um genoma |
| WO2021188840A1 (en) * | 2020-03-19 | 2021-09-23 | Rewrite Therapeutics, Inc. | Methods and compositions for directed genome editing |
| US12115230B2 (en) * | 2020-04-09 | 2024-10-15 | Verve Therapeutics, Inc. | Base editing of ANGPTL3 and methods of using same for treatment of disease |
| BR112023001272A2 (pt) | 2020-07-24 | 2023-04-04 | Massachusetts Gen Hospital | Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| US20230383277A1 (en) * | 2020-10-14 | 2023-11-30 | Beam Therapeutics Inc. | Compositions and methods for treating glycogen storage disease type 1a |
| KR20240012377A (ko) * | 2021-05-28 | 2024-01-29 | 빔 테라퓨틱스, 인크. | 염기 편집기의 자기-불활성화용 조성물 및 방법 |
| AU2022318664A1 (en) | 2021-07-30 | 2024-02-29 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) |
| US20240254483A1 (en) | 2021-07-30 | 2024-08-01 | Tune Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin (fxn) |
| KR20260037664A (ko) | 2021-09-08 | 2026-03-18 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 게놈을 조절하기 위한 방법 및 조성물 |
| US20250223584A2 (en) | 2021-12-03 | 2025-07-10 | The Broad Institute, Inc. | Compositions and methods for efficient in vivo delivery |
| CN117187220A (zh) * | 2022-03-08 | 2023-12-08 | 中国科学院遗传与发育生物学研究所 | 腺嘌呤脱氨酶及其在碱基编辑中的用途 |
| JP2025519070A (ja) | 2022-05-17 | 2025-06-24 | エンヴェロップ セラピューティクス, インコーポレイテッド | 効率的in vivo送達のための組成物および方法 |
| EP4554967A2 (en) | 2022-07-12 | 2025-05-21 | Tune Therapeutics, Inc. | Compositions, systems, and methods for targeted transcriptional activation |
| WO2024097763A1 (en) * | 2022-11-01 | 2024-05-10 | Memorial Sloan-Kettering Cancer Center | Intein-based sorting system and modular chimeric polypeptides |
| WO2024163678A2 (en) | 2023-02-01 | 2024-08-08 | Tune Therapeutics, Inc. | Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods |
| WO2024163683A2 (en) | 2023-02-01 | 2024-08-08 | Tune Therapeutics, Inc. | Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist) |
| WO2024233941A1 (en) * | 2023-05-11 | 2024-11-14 | Massachusetts Eye And Ear Infirmary | Base editing approaches to treat abca4-associated stargardt disease |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| EP4762183A1 (en) * | 2023-08-16 | 2026-06-24 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Systems and methods for improving safety of split intein aav mediated gene therapy |
| CN117568313B (zh) * | 2024-01-15 | 2024-04-26 | 上海贝斯昂科生物科技有限公司 | 基因编辑组合物及其用途 |
| WO2025194124A1 (en) | 2024-03-14 | 2025-09-18 | Tessera Therapeutics, Inc. | Modified st1cas9 guide nucleic acids |
| WO2025194138A1 (en) | 2024-03-14 | 2025-09-18 | Tessera Therapeutics, Inc. | St1cas9 compositions and methods for modulating a genome |
| IT202400011425A1 (it) * | 2024-05-21 | 2025-11-21 | Fondazione St Italiano Tecnologia | Sistema di regolazione genica (tuser) |
| WO2026064753A1 (en) | 2024-09-23 | 2026-03-26 | Tune Therapeutics, Inc. | Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106011104A (zh) | 2015-05-21 | 2016-10-12 | 清华大学 | 利用拆分Cas系统进行基因编辑和表达调控方法 |
| WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
| WO2018035503A1 (en) | 2016-08-18 | 2018-02-22 | The Regents Of The University Of California | Crispr-cas genome engineering via a modular aav delivery system |
| US20180127780A1 (en) | 2016-10-14 | 2018-05-10 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
| US20180155708A1 (en) | 2015-01-08 | 2018-06-07 | President And Fellows Of Harvard College | Split Cas9 Proteins |
Family Cites Families (192)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0329734A (ja) | 1989-06-20 | 1991-02-07 | Kubota Corp | ラベルプリンタ |
| JP2003514564A (ja) | 1999-11-24 | 2003-04-22 | エムシーエス マイクロ キャリア システムズ ゲーエムベーハー | 核局在化シグナルまたはタンパク質導入領域の多量体を含むポリペプチド、および分子を細胞内へ移入するためのその使用法 |
| US20040003420A1 (en) | 2000-11-10 | 2004-01-01 | Ralf Kuhn | Modified recombinase |
| US20050222030A1 (en) | 2001-02-21 | 2005-10-06 | Anthony Allison | Modified annexin proteins and methods for preventing thrombosis |
| CA2439472A1 (en) | 2001-02-27 | 2002-09-06 | University Of Rochester | Methods and compositions for modifying apolipoprotein b mrna editing |
| AU2002330714A1 (en) | 2001-05-30 | 2003-01-02 | Biomedical Center | In silico screening for phenotype-associated expressed sequences |
| US7300829B2 (en) | 2003-06-02 | 2007-11-27 | Applied Materials, Inc. | Low temperature process for TFT fabrication |
| WO2010132092A2 (en) | 2009-05-12 | 2010-11-18 | The Scripps Research Institute | Cytidine deaminase fusions and related methods |
| US20110104787A1 (en) | 2009-11-05 | 2011-05-05 | President And Fellows Of Harvard College | Fusion Peptides That Bind to and Modify Target Nucleic Acid Sequences |
| US20130011380A1 (en) | 2009-12-18 | 2013-01-10 | Blau Helen M | Use of Cytidine Deaminase-Related Agents to Promote Demethylation and Cell Reprogramming |
| WO2012004778A1 (en) | 2010-07-09 | 2012-01-12 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for in-vitro monitoring of neuronal disorders and use thereof |
| JP6177780B2 (ja) | 2011-09-28 | 2017-08-09 | エラ、ビオテック、ソシエダッド、アノニマEra Biotech, S.A. | スプリットインテインおよびその使用 |
| CN103088008B (zh) | 2011-10-31 | 2014-08-20 | 中国科学院微生物研究所 | 胞苷脱氨酶及其编码基因和它们的应用 |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| WO2013188037A2 (en) | 2012-06-11 | 2013-12-19 | Agilent Technologies, Inc | Method of adaptor-dimer subtraction using a crispr cas6 protein |
| PT2877490T (pt) | 2012-06-27 | 2019-02-12 | Univ Princeton | Inteínas clivadas, conjugados e suas utilizações |
| DK3363902T3 (da) | 2012-12-06 | 2020-01-02 | Sigma Aldrich Co Llc | Crispr-baseret genommodifikation og -regulering |
| PT2931898E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| SI2997141T1 (sl) | 2013-05-13 | 2023-04-28 | Cellectis | CD19 specifični himerni antigenski receptor in njegova uporaba |
| WO2014186686A2 (en) | 2013-05-17 | 2014-11-20 | Two Blades Foundation | Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases |
| EP3603679B1 (en) | 2013-06-04 | 2022-08-10 | President and Fellows of Harvard College | Rna-guided transcriptional regulation |
| WO2014197748A2 (en) | 2013-06-05 | 2014-12-11 | Duke University | Rna-guided gene editing and gene regulation |
| JP2016528890A (ja) | 2013-07-09 | 2016-09-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | CRISPR/Cas系を用いるゲノム編集の治療用の使用 |
| US20150044772A1 (en) | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | Crispr/cas system-based novel fusion protein and its applications in genome editing |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| EP3835419A1 (en) | 2013-12-12 | 2021-06-16 | The Regents of The University of California | Methods and compositions for modifying a single stranded target nucleic acid |
| CN111206032B (zh) | 2013-12-12 | 2024-07-19 | 布罗德研究所有限公司 | 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用 |
| ES2918501T3 (es) | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| WO2015092024A2 (en) | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| EP3613854A1 (en) | 2014-03-05 | 2020-02-26 | National University Corporation Kobe University | Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same |
| CN122399016A (zh) | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| WO2015191693A2 (en) | 2014-06-10 | 2015-12-17 | Massachusetts Institute Of Technology | Method for gene editing |
| US10738278B2 (en) | 2014-07-15 | 2020-08-11 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| AU2015298571B2 (en) * | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| WO2016016343A1 (en) | 2014-07-31 | 2016-02-04 | Cellectis | Ror1 specific multi-chain chimeric antigen receptor |
| US10450584B2 (en) | 2014-08-28 | 2019-10-22 | North Carolina State University | Cas9 proteins and guiding features for DNA targeting and genome editing |
| AU2015332533B2 (en) | 2014-10-14 | 2018-08-30 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
| US20170239294A1 (en) | 2014-10-15 | 2017-08-24 | Novartis Ag | Compositions and methods for treating b-lymphoid malignancies |
| EP3212221B1 (en) | 2014-10-29 | 2023-12-06 | Massachusetts Eye & Ear Infirmary | Efficient delivery of therapeutic molecules in vitro and in vivo |
| JP6153180B2 (ja) | 2014-11-04 | 2017-06-28 | 国立大学法人神戸大学 | 脱塩基反応により標的化したdna配列に特異的に変異を導入する、ゲノム配列の改変方法、並びにそれに用いる分子複合体 |
| MA40921A (fr) | 2014-11-05 | 2017-09-12 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation |
| CA2967222C (en) | 2014-11-12 | 2023-10-31 | Rinat Neuroscience Corp. | Inhibitory chimeric antigen receptors |
| US10383929B2 (en) | 2014-12-12 | 2019-08-20 | Bluebird Bio, Inc. | BCMA chimeric antigen receptors |
| AU2015367378A1 (en) | 2014-12-17 | 2017-06-15 | Proqr Therapeutics Ii B.V. | Targeted RNA editing |
| MA41613A (fr) | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| AU2016226077B2 (en) | 2015-03-03 | 2021-12-23 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases with altered PAM specificity |
| WO2016142532A1 (en) | 2015-03-11 | 2016-09-15 | Cellectis | Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients |
| MX2017015239A (es) | 2015-05-29 | 2018-02-19 | Juno Therapeutics Inc | Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas. |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| EP3957731A1 (en) | 2015-07-15 | 2022-02-23 | Rutgers, The State University of New Jersey | Nuclease-independent targeted gene editing platform and uses thereof |
| US9512446B1 (en) | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| CA2999070A1 (en) | 2015-09-17 | 2017-03-23 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| US11008555B2 (en) | 2015-09-17 | 2021-05-18 | The Regents Of The University Of California | Variant Cas9 polypeptides comprising internal insertions |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| MX2018005618A (es) | 2015-11-05 | 2018-08-01 | Juno Therapeutics Inc | Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados. |
| US11020429B2 (en) | 2015-11-05 | 2021-06-01 | Juno Therapeutics, Inc. | Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy |
| US11866727B2 (en) | 2015-11-06 | 2024-01-09 | Crispr Therapeutics Ag | Materials and methods for treatment of glycogen storage disease type 1A |
| WO2017093804A2 (en) | 2015-12-01 | 2017-06-08 | Crispr Therapeutics Ag | Materials and methods for treatment of alpha-1 antitrypsin deficiency |
| WO2017132580A2 (en) | 2016-01-29 | 2017-08-03 | The Trustees Of Princeton University | Split inteins with exceptional splicing activity |
| EP3433364A1 (en) | 2016-03-25 | 2019-01-30 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency |
| ES3030658T3 (en) | 2016-03-30 | 2025-07-01 | Intellia Therapeutics Inc | Lipid nanoparticle formulations for crispr/cas components |
| CA3020993A1 (en) | 2016-04-14 | 2017-10-19 | Bluebird Bio, Inc. | Salvage chimeric antigen receptor systems |
| KR20260004568A (ko) | 2016-04-19 | 2026-01-08 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규한 crispr 효소 및 시스템 |
| CA3026110A1 (en) | 2016-04-19 | 2017-11-02 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
| WO2018020323A2 (en) | 2016-07-25 | 2018-02-01 | Crispr Therapeutics Ag | Materials and methods for treatment of fatty acid disorders |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| US12350349B2 (en) | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| US11352647B2 (en) | 2016-08-17 | 2022-06-07 | The Broad Institute, Inc. | Crispr enzymes and systems |
| WO2018041973A1 (en) | 2016-09-01 | 2018-03-08 | Proqr Therapeutics Ii B.V. | Chemically modified single-stranded rna-editing oligonucleotides |
| MX2019005277A (es) | 2016-11-04 | 2019-09-27 | Bluebird Bio Inc | Composiciones de celulas t con car anti-bcma. |
| US11180778B2 (en) | 2016-11-11 | 2021-11-23 | The Regents Of The University Of California | Variant RNA-guided polypeptides and methods of use |
| CN107043779B (zh) | 2016-12-01 | 2020-05-12 | 中国农业科学院作物科学研究所 | 一种CRISPR/nCas9介导的定点碱基替换在植物中的应用 |
| EP3551757A1 (en) | 2016-12-08 | 2019-10-16 | Intellia Therapeutics, Inc. | Modified guide rnas |
| JP7383478B2 (ja) | 2016-12-22 | 2023-11-20 | インテリア セラピューティクス,インコーポレイテッド | アルファ1アンチトリプシン欠乏症を治療するための組成物および方法 |
| KR102569848B1 (ko) | 2016-12-23 | 2023-08-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Pcsk9의 유전자 편집 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| EP3565608A4 (en) | 2017-01-05 | 2020-12-16 | Rutgers, The State University of New Jersey | TARGETED GENE EDITING PLATFORM INDEPENDENT OF BICATENARY DNA BREAKAGE AND ITS USES |
| WO2018152197A1 (en) | 2017-02-15 | 2018-08-23 | Massachusetts Institute Of Technology | Dna writers, molecular recorders and uses thereof |
| KR102709603B1 (ko) | 2017-02-28 | 2024-09-27 | 보르 바이오파마 인크. | 계통 특이적 단백질의 억제를 위한 조성물 및 방법 |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| CN106916852B (zh) | 2017-04-13 | 2020-12-04 | 上海科技大学 | 一种碱基编辑系统及其构建和应用方法 |
| WO2018195545A2 (en) | 2017-04-21 | 2018-10-25 | The General Hospital Corporation | Variants of cpf1 (cas12a) with altered pam specificity |
| KR102678809B1 (ko) | 2017-05-18 | 2024-06-26 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물 |
| EP3625342B1 (en) | 2017-05-18 | 2022-08-24 | The Broad Institute, Inc. | Systems, methods, and compositions for targeted nucleic acid editing |
| CA3063733A1 (en) | 2017-05-25 | 2018-11-29 | The General Hospital Corporation | Base editors with improved precision and specificity |
| WO2018226602A1 (en) | 2017-06-05 | 2018-12-13 | Research Institute At Nationwide Children's Hospital | Enhanced modified viral capsid proteins |
| CN111328290A (zh) | 2017-06-26 | 2020-06-23 | 博德研究所 | 用于靶向核酸编辑的基于crispr/cas-腺嘌呤脱氨酶的组合物、系统和方法 |
| WO2019005886A1 (en) | 2017-06-26 | 2019-01-03 | The Broad Institute, Inc. | CRISPR / CAS-CYTIDINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED EDITING OF NUCLEIC ACIDS |
| US10392616B2 (en) | 2017-06-30 | 2019-08-27 | Arbor Biotechnologies, Inc. | CRISPR RNA targeting enzymes and systems and uses thereof |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| WO2019040650A1 (en) | 2017-08-23 | 2019-02-28 | The General Hospital Corporation | GENETICALLY MODIFIED CRISPR-CAS9 NUCLEASES HAVING MODIFIED PAM SPECIFICITY |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| IL316453A (en) | 2017-10-06 | 2024-12-01 | Univ Oregon Health & Science | RNA editing agents and methods |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| AR114014A1 (es) | 2017-12-22 | 2020-07-08 | Inst Genetics & Developmental Biology Cas | Sistema de edición de bases y método basado en proteína cpf1 |
| US20210363518A1 (en) | 2018-03-19 | 2021-11-25 | University Of Massachusetts | Modified guide rnas for crispr genome editing |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| KR102853088B1 (ko) | 2018-05-11 | 2025-09-02 | 빔 테라퓨틱스, 인크. | 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일염기다형성을 편집하는 방법 |
| KR102959497B1 (ko) | 2018-05-11 | 2026-05-04 | 빔 테라퓨틱스, 인크. | 프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 돌연변이를 억제하는 방법 |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| KR102894715B1 (ko) | 2018-08-03 | 2025-12-03 | 빔 테라퓨틱스, 인크. | 핵산 표적 서열을 변형시키기 위한 다중-이펙터 핵염기 편집기 및 이를 이용하는 방법 |
| WO2020041751A1 (en) | 2018-08-23 | 2020-02-27 | The Broad Institute, Inc. | Cas9 variants having non-canonical pam specificities and uses thereof |
| US11530245B2 (en) | 2018-08-31 | 2022-12-20 | Washington University | Split intein mediated polymerization and production of mussel foot adhesive protein materials |
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| CN109295186B (zh) | 2018-09-30 | 2023-10-03 | 中山大学 | 一种基于全基因组测序检测腺嘌呤单碱基编辑系统脱靶效应的方法及其在基因编辑中的应用 |
| CA3116606A1 (en) | 2018-10-15 | 2020-04-23 | Fondazione Telethon | Intein proteins and uses thereof |
| KR20210094609A (ko) | 2018-11-28 | 2021-07-29 | 포티 세븐, 인코포레이티드 | 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc |
| EP3887521A1 (en) | 2018-11-29 | 2021-10-06 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| US11667682B2 (en) | 2018-12-13 | 2023-06-06 | Washington University | Split intein mediated protein polymerization for microbial production of materials |
| WO2020146627A1 (en) | 2019-01-10 | 2020-07-16 | California Institute Of Technology | A synthetic system for tunable thresholding of protein signals |
| AU2020216484A1 (en) | 2019-01-31 | 2021-07-29 | Beam Therapeutics Inc. | Nucleobase editors having reduced off-target deamination and methods of using same to modify a nucleobase target sequence |
| JP7646552B2 (ja) | 2019-01-31 | 2025-03-17 | ビーム セラピューティクス インク. | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ |
| WO2020163396A1 (en) | 2019-02-04 | 2020-08-13 | The General Hospital Corporation | Adenine dna base editor variants with reduced off-target rna editing |
| US20220098593A1 (en) | 2019-02-13 | 2022-03-31 | Beam Therapeutics Inc. | Splice acceptor site disruption of a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease |
| WO2020168135A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| CN114040970B (zh) | 2019-02-13 | 2024-09-27 | 比姆医疗股份有限公司 | 使用腺苷脱氨酶碱基编辑器编辑疾病相关基因的方法,包括遗传性疾病的治疗 |
| US20220127594A1 (en) | 2019-02-13 | 2022-04-28 | Beam Therapeutics Inc. | Compositions and methods for treating glycogen storage disease type 1a |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| CN114096666B (zh) | 2019-02-13 | 2025-03-18 | 比姆医疗股份有限公司 | 治疗血红素病变的组合物和方法 |
| EP3924479A4 (en) | 2019-02-13 | 2023-01-25 | Beam Therapeutics, Inc. | ADENOSINE DEAMINASE BASE EDITORS AND METHODS OF USING THEM TO MODIFY A NUCLEOBASE IN A TARGET SEQUENCE |
| KR102129377B1 (ko) | 2019-02-21 | 2020-07-02 | 성균관대학교산학협력단 | 특정 특성이 발현된 단백질을 암호화하는 플라스미드를 선별하는 유도 플라스미드 디스플레이 시스템 |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| JP7679309B2 (ja) | 2019-05-10 | 2025-05-19 | ビーム セラピューティクス インク. | B型肝炎を治療するための組成物及び方法 |
| WO2020236982A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Aav delivery of nucleobase editors |
| JP7679311B2 (ja) | 2019-05-21 | 2025-05-19 | ビーム セラピューティクス インク. | プログラム可能塩基エディターシステムを用いた一塩基多型編集法 |
| US20220259617A1 (en) | 2019-06-13 | 2022-08-18 | The General Hospital Corporation | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| CA3147875A1 (en) | 2019-07-19 | 2021-01-28 | Flagship Pioneering Innovations Vi, Llc | Recombinase compositions and methods of use |
| AU2020322021A1 (en) | 2019-07-30 | 2022-02-10 | Pairwise Plants Services, Inc. | Morphogenic regulators and methods of using the same |
| KR102258713B1 (ko) | 2019-07-31 | 2021-05-31 | 한양대학교 산학협력단 | 사이토신 염기교정용 조성물 및 이의 용도 |
| CN119913134A (zh) | 2019-08-29 | 2025-05-02 | 比姆医疗股份有限公司 | 用于编辑突变以允许转录或表达的组合物和方法 |
| US20220290121A1 (en) | 2019-08-30 | 2022-09-15 | The General Hospital Corporation | Combinatorial Adenine and Cytosine DNA Base Editors |
| AU2020344547A1 (en) | 2019-09-09 | 2022-03-24 | Beam Therapeutics Inc. | Novel nucleobase editors and methods of using same |
| AU2020466994B2 (en) | 2019-09-17 | 2026-05-28 | Rutgers, The State University Of New Jersey | Highly efficient DNA base editors mediated by RNA-aptamer recruitment for targeted genome modification and uses thereof |
| CN114667293A (zh) | 2019-09-24 | 2022-06-24 | Mvrix株式会社 | 抗病毒活性增强的纳米穿孔器 |
| US12594301B2 (en) | 2019-09-27 | 2026-04-07 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| US11591607B2 (en) | 2019-10-24 | 2023-02-28 | Pairwise Plants Services, Inc. | Optimized CRISPR-Cas nucleases and base editors and methods of use thereof |
| CN114867852A (zh) | 2019-10-30 | 2022-08-05 | 成对植物服务股份有限公司 | V型crispr-cas碱基编辑器及其使用方法 |
| EP4061940A4 (en) | 2019-11-22 | 2024-10-23 | Flagship Pioneering Innovations VI, LLC | RECOMBINASE COMPOSITIONS AND METHODS OF USE |
| WO2021108717A2 (en) | 2019-11-26 | 2021-06-03 | The Broad Institute, Inc | Systems and methods for evaluating cas9-independent off-target editing of nucleic acids |
| GB201918693D0 (en) | 2019-12-18 | 2020-01-29 | Univ Southampton | Peptide |
| US20230235309A1 (en) | 2020-02-05 | 2023-07-27 | The Broad Institute, Inc. | Adenine base editors and uses thereof |
| AU2021232005A1 (en) | 2020-03-04 | 2022-09-29 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for modulating a genome |
| IL296095A (en) | 2020-03-04 | 2022-11-01 | Flagship Pioneering Innovations Vi Llc | Improved methods and compositions for genome modulation |
| BR112022017715A2 (pt) | 2020-03-04 | 2022-11-16 | Flagship Pioneering Innovations Vi Llc | Métodos e composições para modular um genoma |
| BR112022017735A2 (pt) | 2020-03-05 | 2022-11-29 | Flagship Pioneering Innovations Vi Llc | Métodos e composições de supressão de defesa de hospedeiro para modular um genoma |
| WO2021188840A1 (en) | 2020-03-19 | 2021-09-23 | Rewrite Therapeutics, Inc. | Methods and compositions for directed genome editing |
| EP3885440A1 (en) | 2020-03-26 | 2021-09-29 | Splicebio, S.L. | Split inteins and their uses |
| EP4132951A4 (en) | 2020-04-09 | 2025-06-11 | Verve Therapeutics, Inc. | CHEMICALLY MODIFIED GENE EDITING GUIDE RNAS WITH CAS12B |
| WO2021209574A1 (en) | 2020-04-15 | 2021-10-21 | Fondazione Telethon | Constructs comprising inteins |
| WO2021222318A1 (en) | 2020-04-28 | 2021-11-04 | The Broad Institute, Inc. | Targeted base editing of the ush2a gene |
| EP4179079A1 (en) | 2020-07-10 | 2023-05-17 | Horizon Discovery Limited | Method for producing genetically modified cells |
| JP7890972B2 (ja) | 2020-07-15 | 2026-07-15 | ライフ エディット セラピューティクス,インコーポレイティド | ウラシル安定化タンパク質並びにその活性断片及びバリアント並びに使用方法 |
| BR112023001272A2 (pt) | 2020-07-24 | 2023-04-04 | Massachusetts Gen Hospital | Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células |
| CA3192224A1 (en) | 2020-09-11 | 2022-03-17 | Jyun-Liang LIN | Base editing enzymes |
| EP4211235A2 (en) | 2020-09-11 | 2023-07-19 | Lifeedit Therapeutics, Inc. | Dna modifying enzymes and active fragments and variants thereof and methods of use |
| US20230383277A1 (en) | 2020-10-14 | 2023-11-30 | Beam Therapeutics Inc. | Compositions and methods for treating glycogen storage disease type 1a |
| IT202000028688A1 (it) | 2020-11-27 | 2022-05-27 | Consiglio Nazionale Ricerche | Varianti della citidina deaminasi per l’editazione di basi |
| EP4274902A4 (en) | 2021-01-05 | 2025-04-16 | Revvity Discovery Limited | Guide RNA designs and complexes for tracless V-CAS systems |
| US20240060088A1 (en) | 2021-01-05 | 2024-02-22 | Horizon Discovery Limited | Guide RNA Designs and Complexes for Type V Cas Systems |
| CA3207144A1 (en) | 2021-01-05 | 2022-07-14 | Horizon Discovery Limited | Method for producing genetically modified cells |
| WO2022150706A2 (en) | 2021-01-08 | 2022-07-14 | The General Hospital Corporation | Genome editing approaches to treat spinal muscular atrophy |
| JP2024507533A (ja) | 2021-02-19 | 2024-02-20 | ビーム・セラピューティクス・インコーポレイテッド | 遺伝子治療のための組み換え狂犬病ウイルス |
| BR112023019539A2 (pt) | 2021-03-26 | 2023-12-05 | Beam Therapeutics Inc | Variantes de adenosina desaminase e usos das mesmas |
| CN113813398B (zh) | 2021-04-23 | 2023-11-07 | 天津医科大学 | 一种向表面富含神经节苷脂的细胞递送重组蛋白质的方法 |
| WO2023279118A2 (en) | 2021-07-02 | 2023-01-05 | University Of Maryland, College Park | Cytidine deaminases and methods of genome editing using the same |
| CA3225808A1 (en) | 2021-07-16 | 2023-01-19 | David R. Liu | Context-specific adenine base editors and uses thereof |
| CN113480613B (zh) | 2021-08-04 | 2022-04-15 | 江南大学 | 一种自剪切蛋白标签、改造方法及其应用 |
| CN113735941B (zh) | 2021-08-13 | 2024-01-30 | 江南大学 | 一种蛋白纯化方法及其应用 |
| EP4396207A4 (en) | 2021-09-03 | 2025-07-16 | Univ Chicago | POLYPEPTIDES AND METHODS FOR MODIFYING NUCLEIC ACIDS |
| GB2702733A (en) | 2021-09-22 | 2026-06-24 | Verve Therapeutics Inc | Gene editing of PCSK9 or ANGPTL3 and compositions and methods of using same for treatment of disease |
| US20230105319A1 (en) | 2021-09-24 | 2023-04-06 | Crispr Therapeutics Ag | PRODRUG INCORPORATED sgRNA SYNTHESIS |
| WO2023125814A1 (zh) | 2021-12-29 | 2023-07-06 | 华东师范大学 | 腺嘌呤脱氨酶及其应用 |
| WO2023155901A1 (en) | 2022-02-17 | 2023-08-24 | Correctsequence Therapeutics | Mutant cytidine deaminases with improved editing precision |
| CN114634923B (zh) | 2022-04-07 | 2024-02-23 | 尧唐(上海)生物科技有限公司 | 腺苷脱氨酶、碱基编辑器融合蛋白、碱基编辑器系统及用途 |
| JP2025517515A (ja) | 2022-05-26 | 2025-06-05 | ユーシービー バイオファルマ エスアールエル | 新規核酸編集タンパク質 |
| EP4540378A1 (en) | 2022-06-20 | 2025-04-23 | CRISPR Therapeutics AG | Base editing proteins and uses thereof |
| JP2025520697A (ja) | 2022-06-23 | 2025-07-03 | ビーエーエスエフ アグリカルチュラル ソリューションズ ユーエス エルエルシー | 多様化塩基編集 |
| AU2023325079A1 (en) | 2022-08-16 | 2025-02-13 | President And Fellows Of Harvard College | Evolved cytosine deaminases and methods of editing dna using same |
| WO2024063273A1 (en) | 2022-09-23 | 2024-03-28 | Institute For Basic Science | Novel adenine deaminase variants and a method for base editing using the same |
| CN120435553A (zh) | 2022-09-26 | 2025-08-05 | 比姆医疗股份有限公司 | 合成多肽及其用途 |
| WO2024179426A2 (en) | 2023-02-28 | 2024-09-06 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Deaminases for use in base editing |
| WO2024226156A1 (en) | 2023-04-27 | 2024-10-31 | University Of Massachusetts | Cas-embedded cytidine deaminase ribonucleoprotein complexes having improved base editing specificity and efficiency |
| KR20260007576A (ko) | 2023-04-28 | 2026-01-14 | 빔 테라퓨틱스, 인크. | 변형된 가이드 rna |
| CN121889499A (zh) | 2023-06-15 | 2026-04-17 | 比姆医疗股份有限公司 | 用于治疗α1-抗胰蛋白酶缺乏症的方法和组合物 |
| CN117965505A (zh) | 2023-06-28 | 2024-05-03 | 微光基因(苏州)有限公司 | 工程化的腺苷脱氨酶及碱基编辑器 |
-
2019
- 2019-09-07 KR KR1020217009863A patent/KR20210055733A/ko not_active Ceased
- 2019-09-07 CA CA3112011A patent/CA3112011A1/en active Pending
- 2019-09-07 JP JP2021512514A patent/JP7657711B2/ja active Active
- 2019-09-07 AU AU2019336245A patent/AU2019336245B2/en active Active
- 2019-09-07 US US17/273,209 patent/US12529041B2/en active Active
- 2019-09-07 CN CN201980073055.6A patent/CN112969790B/zh active Active
- 2019-09-07 EP EP19857653.0A patent/EP3847254A4/en active Pending
- 2019-09-07 WO PCT/US2019/050111 patent/WO2020051561A1/en not_active Ceased
-
2024
- 2024-11-01 JP JP2024192680A patent/JP7899276B2/ja active Active
-
2025
- 2025-12-12 US US19/418,220 patent/US20260176605A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180155708A1 (en) | 2015-01-08 | 2018-06-07 | President And Fellows Of Harvard College | Split Cas9 Proteins |
| CN106011104A (zh) | 2015-05-21 | 2016-10-12 | 清华大学 | 利用拆分Cas系统进行基因编辑和表达调控方法 |
| US20170233703A1 (en) | 2015-05-21 | 2017-08-17 | Tsinghua University | Genetic indicator and control system and method utilizing split Cas9/CRISPR domains for transcriptional control in eukaryotic cell lines |
| WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
| WO2018035503A1 (en) | 2016-08-18 | 2018-02-22 | The Regents Of The University Of California | Crispr-cas genome engineering via a modular aav delivery system |
| US20180127780A1 (en) | 2016-10-14 | 2018-05-10 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
Non-Patent Citations (3)
| Title |
|---|
| FINE, Eli J. et al.,Scientific Reports,2015年07月01日,Vol. 5, No. 1,pp. 1 - 9,DOI: 10.1038/srep10777 |
| MA, Dacheng et al.,Nature Communications,2016年10月03日,Vol. 7, Article No. 13056,DOI: 10.1038/ncomms13056 |
| TRUONG, Dong-Jiunn Jeffery et al.,Nucleic Acids Research,2015年06月16日,Vol. 43, No. 13,pp. 6450 - 6458,DOI: 10.1093/nar/gkv601 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025028857A (ja) * | 2018-09-07 | 2025-03-05 | ビーム セラピューティクス インク. | 核酸塩基編集システムを送達するための組成物および方法 |
| JP7899276B2 (ja) | 2018-09-07 | 2026-08-03 | ビーム セラピューティクス インク. | 核酸塩基編集システムを送達するための組成物および方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210055733A (ko) | 2021-05-17 |
| EP3847254A1 (en) | 2021-07-14 |
| CN112969790B (zh) | 2024-07-05 |
| AU2019336245B2 (en) | 2026-02-26 |
| US20210301274A1 (en) | 2021-09-30 |
| JP2025028857A (ja) | 2025-03-05 |
| CA3112011A1 (en) | 2020-03-12 |
| US20260176605A1 (en) | 2026-06-25 |
| JP2022500017A (ja) | 2022-01-04 |
| AU2019336245A1 (en) | 2021-04-01 |
| EP3847254A4 (en) | 2022-08-10 |
| US12529041B2 (en) | 2026-01-20 |
| JP7899276B2 (ja) | 2026-08-03 |
| CN112969790A (zh) | 2021-06-15 |
| WO2020051561A1 (en) | 2020-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019336245B2 (en) | Compositions and methods for delivering a nucleobase editing system | |
| JP7717684B2 (ja) | 新規核酸塩基エディター及びその使用方法 | |
| JP7646552B2 (ja) | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ | |
| AU2023229577B2 (en) | Compositions and methods for treating hemoglobinopathies | |
| US12454694B2 (en) | Compositions and methods for improving base editing | |
| CN114026237B (zh) | 用于治疗1a型糖原贮积病的组成物和方法 | |
| US12622931B2 (en) | Compositions and methods for treating alpha-1 antitrypsin deficiency | |
| US20220387622A1 (en) | Methods of editing a single nucleotide polymorphism using programmable base editor systems | |
| CA3108281A1 (en) | Multi-effector nucleobase editors and methods of using same to modify a nucleic acid target sequence | |
| CN120400115A (zh) | 脱氨反应脱靶减低的核碱基编辑器和使用其修饰核碱基靶序列的方法 | |
| KR20230158476A (ko) | 유전자 요법을 위한 재조합 광견병 바이러스 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220906 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220906 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231108 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240416 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240702 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241101 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20241129 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250225 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250326 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7657711 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |